FRAMINGHAM, MA - This week, Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced that it is investing $80 million to build a new downstream processing facility for Fabrazyme® (agalsidase beta).
The new plant, which will be located adjacent to the new Fabrazyme cell culture manufacturing site in Framingham, Massachusetts, will significantly expand purification capacity to support anticipated growth in global demand over the coming years.
“As we continue to meet the global demands for Fabrazyme and build inventory, our focus also remains on the future needs of the global Fabry community,” said Genzyme President and CEO, David Meeker, M.D. “Following last year’s regulatory approvals of our manufacturing facility in Framingham and a new vial filling line at our plant in Waterford, Ireland, we continue to execute on our global manufacturing strategy, enhancing our capabilities across the entire manufacturing process for Fabrazyme.”
Downstream processing, a vital step in biologic production, involves the purification of material harvested from the cell culture manufacturing process. The final product, which is administered as an intravenous (IV) infusion, is formulated and fill-finished in a separate facility in Waterford, Ireland and shipped to multiple distribution centers for labeling, packaging and shipping around the world.
About Fabry Disease
Fabrazyme is approved for treatment of Fabry disease, an inherited condition that is characterized by excessive accumulation of the lipid GL-3 in various organs and tissues, which over time can cause renal, cardiac and cerebrovascular events. As a result, patients with Fabry disease typically have a shortened life span, and children must often cope with significant pain and disability. Fabry disease is an inherited and life threatening disease linked to the X chromosome which affects approximately 5,000 patients in the world.
About Genzyme, a Sanofi Company
Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzyme’s portfolio of transformative therapies, which are marketed in countries around the world, represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients.
Genzyme® and Fabrazyme® are registered trademarks of Genzyme Corporation. All rights reserved. For additional info, visit the Genzyme website at: www.genzyme.com